2/26
04:35 pm
vnda
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Medium
Report
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
2/25
07:32 am
vnda
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]
2/25
07:18 am
vnda
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Low
Report
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
2/23
07:17 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/20
09:42 pm
vnda
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug [Yahoo! Finance]
2/20
05:59 pm
vnda
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
High
Report
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
2/20
07:28 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/19
08:10 am
vnda
Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week [Seeking Alpha]
Low
Report
Vanda Pharma: High Risk, Heavily Discounted - Stock Ahead Of PDUFA This Week [Seeking Alpha]
2/14
10:30 am
vnda
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/14
02:07 am
vnda
Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Vanda Pharmaceuticals Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/14
01:32 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at
Wall S
2/13
07:41 am
vnda
Cybin GAAP EPS of -$1.00 misses by $0.41 [Seeking Alpha]
Low
Report
Cybin GAAP EPS of -$1.00 misses by $0.41 [Seeking Alpha]
2/13
06:29 am
vnda
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
2/12
06:56 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
2/11
06:41 pm
vnda
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
High
Report
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
2/11
06:28 pm
vnda
Vanda Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Vanda Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/11
04:16 pm
vnda
Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M [Seeking Alpha]
High
Report
Vanda Pharmaceuticals GAAP EPS of -$2.39 misses by $1.07, revenue of $57.22M misses by $2.05M [Seeking Alpha]
2/11
04:01 pm
vnda
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
High
Report
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
2/4
06:01 pm
vnda
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Medium
Report
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
2/3
01:40 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/29
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/27
01:08 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/22
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/20
01:11 pm
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
1/15
10:00 am
vnda
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA